Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

Predicting Heart Attack Risk with CT Angiography

By Medimaging International staff writers
Posted on 25 Feb 2013
Coronary computed tomography angiography (CCTA) is an effective tool for determining the risk of myocardial infarctions and other abnormal cardiac events in patients with suspected coronary artery disease (CAD) but no treatable risk factors, such as high blood pressure or high cholesterol.

“CCTA should be considered as an appropriate first-line test for patients with atypical chest pain and suspected but not confirmed coronary artery disease,” said the study’s lead author, Jonathon Leipsic, MD, FRCPC, from the University of British Columbia (Vancouver, BC, Canada).

Treatment for heart disease typically involves tackling modifiable cardiovascular risk factors such as high blood pressure, elevated cholesterol, diabetes, and smoking. However, some risk factors, such as family history, are not modifiable, and no risk models exist to help guide clinicians to identify those symptomatic patients without cardiac risk factors who are at an increased risk of death and myocardial infarction. “This scenario, where patients are symptomatic but have no cardiac risk factors, comes up often in clinical practice,” Dr. Leipsic said. “We lack a good tool to stratify these patients into risk groups.”

CCTA is a noninvasive test that has shown high accuracy for the diagnosis or exclusion of coronary artery disease in individuals. However, referral for patients with suspected coronary artery disease is frequently based on clinical risk factor scoring. Less is known about the prognostic benefits of CCTA in individuals with no medically modifiable risk factors.

In the first study of its sort, published online February 2013 in the journal Radiology, Dr. Leipsic and colleagues correlated CCTA results with the risk of major adverse cardiac events in 5,262 patients with suspected coronary artery disease but no medically modifiable risk factors. They culled the data from the Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter (CONFIRM) registry.

After a median follow-up of 2.3 years, 104 patients had experienced a major adverse cardiovascular event. The researchers identified a high occurrence of CAD in the study group, in spite of the lack of modifiable risk factors. More than 25% of the patients had non-obstructive disease or disease related to the accumulation of plaque in the arteries, and another 12% had obstructive disease with a greater than 50% narrowing in a coronary artery. “We found that patients with narrowing of the coronary arteries on CT had a much higher risk of an adverse cardiac event,” Dr. Leipsic said. “This was true even for those without a family history of heart disease.”

Both asymptomatic and symptomatic patients with obstructive disease faced an increased risk for a major cardiac event. Contrarily, the absence of CAD on CCTA was associated with a very low risk of a major event.

The findings, according to the investigators, emphasize the need for improvement in the evaluation of individuals who may be overlooked by conventional techniques of CAD assessment. “If a patient shows up with vague symptoms and no medically modifiable risk factors, doctors often dismiss them or do a treadmill test, which won’t identify atherosclerosis and only has a modest sensitivity for detecting obstructive disease,” Dr. Leipsic said.

CCTA could help address this problem, Dr. Leipsic added, by helping to detect or rule out coronary artery disease and identifying those who may be helped with more intensive therapy. The researchers continue to examine the CONFIRM data with the goal of further clarifying the association between plaque and myocardial infarctions and the longer-term outlook for patients with coronary artery disease.

“We are now collecting data to determine the prognostic value of CCTA after five years or more of follow-up, which will be very important for the field,” Dr. Leipsic stated.

Related Links:
University of British Columbia



SuperSonic Imagine
RTI ELECTRONICS AB
RADCAL

Channels

MRI

view channel
Image: The quantitative character of the novel 3D technique on MR scans from a patient with primary liver cancer is demonstrated. Images A and B show the scan of the patient before being treated with chemoembolization. The new 3D technique helped quantify the volume and distribution of viable tumor tissue (shown in red and yellow colors). Images C and D demonstrate MR scans acquired after the treatment. The new 3D method helped the radiologists to quantify the vast central destruction of the tumor after the treatment (the dead tumor is represented by the blue color) (Photo courtesy of Johns Hopkins Medicine).

3D MRI Offers Improved Prediction of Survival After Chemotherapy for Liver Tumors

Researchers are using specialized three-dimensional (3D) magnetic resonance imaging (MRI) scanning technology to accurately measure living and dying liver tumor tissue in order to quickly show whether... Read more

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.